CG
VRTX icon

Clinton Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Clinton Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,576
Closed -$257K – 480
2018
Q1 		$257K Sell
1,576
-36,964
-96% -$6.04M 0.03% 319
2017
Q4 		$5.78M Buy
38,540
+34,995
+987% +$5.18M 0.52% 58
2017
Q3 		$539K Buy
+3,545
New +$534K 0.06% 282
2017
Q2 		– Sell
-11,000
Closed -$1.2M – 888
2017
Q1 		$1.2M Buy
+11,000
New +$968K 0.07% 385
2016
Q4 		– Sell
-6,461
Closed -$563K – 1028
2016
Q3 		$563K Buy
+6,461
New +$611K 0.03% 645

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return